Fårup, October 15, 2025
Majority stake in Danish DermaPharm sold
to international private equity firm ARCHIMED
The Danish company DermaPharm – known for its reputable skincare brands Derma and DermaKnowlogy as well as its extensive private label production – has on October 15, 2025, been acquired by the global private equity firm ARCHIMED.
ARCHIMED specializes in healthcare investments and holds a diverse portfolio of health-promoting companies serving both end consumers and the healthcare sector.
Since 1980, DermaPharm has established itself as Denmark’s leading producer of environmentally friendly sun care and skincare products, supplying both the healthcare sector and retail markets. With an average annual revenue growth of around 14 percent over the past decade, the company is in a strong position.
The sales process, supported by Clearwater, was very positive for DermaPharm A/S, with several interested parties emerging. Ultimately, DermaPharm chose to proceed with ARCHIMED.
“With ARCHIMED, we gain the opportunity to grow and develop even further. They can help us open more doors to international markets, and we’ll be able to exchange knowledge across the ARCHIMED group. Overall, they bring a strong scientific foundation that we can draw on and develop with,” says DermaPharm CEO Mikkel Egelund Jensen, who expects continued growth in the number of employees at the company’s factory north of Randers.
“At the same time, it’s a huge vote of confidence in everyone at DermaPharm. The process has shown that we are a well-organized, well-run company. Now, our focus will be on strengthening our partnerships even more and expanding our customer base across Europe – something we’re truly looking forward to,” he adds.
Mikkel Egelund Jensen also emphasizes that there are no plans or ambitions to relocate the company from its current site in Fårup, where preparations are already underway to significantly expand production and warehouse capacity in the coming years.
Expanding presence in Scandinavia
For ARCHIMED, the acquisition marks its third investment in Scandinavia.
“DermaPharm represents a unique opportunity to acquire a clean-label, strategically positioned sun care and skincare CDMO platform with exceptional expertise in innovation, development, and manufacturing,” says Jean Yves Desmottes, Partner at ARCHIMED. “We believe the company’s unique, pioneering, and environmentally friendly skincare products have significant growth potential – not only in Scandinavia, but throughout Europe.”
Daily operations continue in Fårup
CEO Mikkel Egelund Jensen, COO Peter Bogh Lindgaard, and the rest of DermaPharm’s management team will continue in their current roles. The two directors will retain a significant ownership stake in the company going forward. ARCHIMED will take a seat on the board but will not be involved in daily operations.
The sale to ARCHIMED follows the wish of former majority owners Birger and Annette Kuntkes, who decided to divest their shares after 12 years of ownership. The remaining shares of the company are owned by Mikkel Egelund Jensen.
About ARCHIMED
ARCHIMED is a global investment firm focused exclusively on the healthcare industry.
“We partner with scientists, healthcare professionals, entrepreneurs, and investors. Together, we support companies in their next growth phase through strategic tools such as internationalization, innovation, mergers and acquisitions, and more.”
About DermaPharm
DermaPharm develops and manufactures clean, effective, and high-quality skincare products that care for both health and the environment. Today, DermaPharm is the innovative market leader in gentle, environmentally friendly skincare in Scandinavia and has received multiple awards for its certified skincare products.
For more information, please contact:
Mikkel Egelund Jensen, CEO
📧 [email protected]
📞 +45 86 47 77 44
Press photos are available for download here:
https://dermapharm-dk.com/press-room